AWH - Aspira Women's Health Expands Senior Leadership Team with the Addition of Sandra Milligan M.D. J.D. as President | Benzinga
Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors
Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company's product development team following the departure of Dr. Jody Berry
AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company's product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
Dr. Milligan is an accomplished and proven leader with 25+ years of experience in the healthcare sector, with corporate experience that includes executive roles of increasing responsibility at innovative biopharmaceutical companies such as Amgen, Genentech, Merck, and Organon. She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women's health. Dr. Milligan is a known and respected leader in women's health who drives cross-functional strategies to achieve corporate success.
As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions. Her immediate focus will be on accelerating the launch of the Company's in-development products and the identification of potential innovation and commercialization partnerships.
"I am thrilled to welcome Sandy to our senior leadership team. She is a dynamic executive with the depth and breadth of experience and pharmaceutical and women's health industry relationships we need to take advantage of the opportunities before us," said Nicole Sandford, Chief Executive Officer of Aspira. "With Sandy focused on the successful achievement of our innovation and operational goals, I will direct more of my attention on the acceleration of our growth initiatives, the expansion of our shareholder base, and the achievement of our long-term vision as a world-class AI-driven diagnostic company. She joins an already strong executive leadership team of experienced professionals. I also congratulate Todd who takes his rightful place at the helm of our R&D effort having been ...